Moleculin Biotech Inc reports results for the quarter - Earnings Summary

Moleculin Biotech

11/11/2024 15:33

* Moleculin Biotech Inc  MBRX.OQ  reported a quarterly
adjusted
loss of $2.85​​ per share for the quarter , identical to the
same quarter last year.  The mean expectation of two analysts
for the quarter was for a loss of $2.44 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Moleculin Biotech Inc's reported EPS for the quarter was a
loss
of $2.85​.
    * The company reported a quarterly loss of $10.59 million.
    * Moleculin Biotech Inc shares had fallen by 10.2% this
quarter and lost 80.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 5.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Moleculin Biotech
Inc is $30.00 
This summary was machine generated from LSEG data November 11 at
03:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -2.44          -2.85          Missed
 Jun. 30 2024      -2.51          -1.70          Beat
 Mar. 31 2024      -3.53          -2.02          Beat
 Dec. 31 2023      -3.05          -5.02          Missed